Research graph
References from Cell Therapy for Heart Failure With Preserved Ejection Fraction. Local targets link to admitted publications; unresolved targets remain external evidence.
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
10.1093/eurheartj/ehq426 · 2011 · External reference
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
10.1016/j.jacc.2013.02.092 · 2013 · External reference
The pathophysiology of heart failure with preserved ejection fraction
10.1038/nrcardio.2014.83 · 2014 · External reference
Cell therapy for cardiac repair—lessons from clinical trials
10.1038/nrcardio.2014.9 · 2014 · External reference
Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells
10.1016/j.mayocp.2014.02.014 · 2014 · External reference
Cardiosphere-derived cells reverse heart failure with preserved ejection fraction in rats by decreasing fibrosis and inflammation
2016 · External reference
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance
10.1152/ajpheart.01017.2005 · 2006 · External reference
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction
10.1016/j.jacc.2009.05.013 · 2009 · External reference
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion
10.1016/j.jacc.2009.03.037 · 2009 · External reference
Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction
10.1016/j.jacc.2010.03.077 · 2010 · External reference
Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone
10.1161/circulationaha.115.015884 · 2015 · External reference
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction
10.1161/circulationaha.106.632745 · 2006 · External reference
Right heart dysfunction in heart failure with preserved ejection fraction
10.1093/eurheartj/ehu193 · 2014 · External reference
Right ventricular function in heart failure with preserved ejection fraction: a community-based study
10.1161/circulationaha.113.008461 · 2014 · External reference
Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction
10.1161/circheartfailure.114.002114 · 2015 · External reference
Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction
10.1016/j.jacc.2011.02.055 · 2011 · External reference
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction
10.1161/circheartfailure.114.001825 · 2015 · External reference
Phenomapping for novel classification of heart failure with preserved ejection fraction
10.1161/circulationaha.114.010637 · 2015 · External reference
Matchmaking for the optimization of heart failure with preserved ejection fraction clinical trials: no laughing matter
10.1016/j.jacc.2013.07.010 · 2013 · External reference
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction
10.1161/circulationaha.114.009625 · 2015 · External reference
